A landmark individual participant data meta-analysis examining 51 randomized controlled trials has quantified an important pattern in antihypertensive therapy outcomes. The relative risk reduction for cardiovascular events reaches 28 percent in years one to two, increases modestly to 31 percent in years two to four, then plateaus at 29 percent beyond year four. This plateau pattern, published in Nature Medicine in 2026, fundamentally challenges the clinical assumption that extended treatment duration automatically translates to proportional cardiovascular benefit.
The data encompass tens of thousands of trial participants across diverse populations, providing robust evidence that early blood pressure control may be more clinically significant than indefinite intensification. These findings suggest that treatment strategies focused on rapid achievement of target blood pressure, followed by reassessment rather than automatic continuation, may better serve patient outcomes while reducing unnecessary medication burden.
Read the full article on GMJ Newsroom.
Was this article helpful?
